SCHEMBL16596104

SCHEMBL16596104

c1cc2c(-c3cn[nH]c3)c[nH]c2cn1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 11/20 0.70
NFATC1 O95644 6/20 0.70
GSK3B P49841 4/20 0.70
PDPK1 O15530 1/20 0.53
TGFBR1 P36897 1/20 0.53
IKBKE Q14164 1/20 0.53
CDK2 P24941 2/20 0.50
DYRK1B Q9Y463 2/20 0.50
MAPT P10636 1/20 0.50
IGF1R P08069 1/20 0.50
AURKA O14965 1/20 0.49
AURKB Q96GD4 1/20 0.49
INCENP Q9NQS7 1/20 0.49
TPX2 Q9ULW0 1/20 0.49
HTR2A P28223 1/20 0.48
MAPK1 P28482 2/20 0.47
IMPDH2 P12268 1/20 0.47
HSD17B10 Q99714 1/20 0.47
PIM1 P11309 1/20 0.45
HASPIN Q8TF76 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25421202 0.82 DYRK1A (1.00) DYRK1ANFATC1GSK3BPDPK1TGFBR1
SCHEMBL30461701 0.82 DYRK1A (1.00) DYRK1ANFATC1GSK3BPDPK1TGFBR1
SCHEMBL16697582 0.79 IMPDH2 (0.59) GSK3BMAPTMAPK1IMPDH2HSD17B10
SCHEMBL29563848 0.79 IMPDH2 (0.59) GSK3BMAPTMAPK1IMPDH2HSD17B10
SCHEMBL26696137 0.79 DYRK1A (0.80) DYRK1ANFATC1GSK3BPDPK1TGFBR1
SCHEMBL17179566 0.78 DYRK1A (1.00) DYRK1ANFATC1GSK3BPDPK1TGFBR1
SCHEMBL30557126 0.77 BRD4 (0.55) DYRK1ANFATC1GSK3BCDK2DYRK1B
SCHEMBL10270837 0.76 MAP3K7 (0.49) DYRK1ANFATC1GSK3BAURKB
SCHEMBL16708697 0.74 TDO2 (0.49) DYRK1ANFATC1HTR2AIMPDH2PIM1
SCHEMBL16697436 0.74 TDO2 (0.61) TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260007634-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ALLERGIC DISEASES KINKI UNIVERSITY (JP) 2026-01-08 US disclosed
EP-4566599-A1 PHARMACEUTICAL COMPOSITION FOR AMELIORATING ALLERGIC DISEASES Kinki University (JP) 2025-06-11 EP disclosed
US-20240124430-A1 PHARMACEUTICAL COMPOSITION FOR AMELIORATING MALIGNANT DISEASES KINKI UNIVERSITY (JP) 2024-04-18 US disclosed
WO-2024029528-A1 PHARMACEUTICAL COMPOSITION FOR AMELIORATING ALLERGIC DISEASES 学校法人近畿大学 2024-02-08 WO disclosed
WO-2023234312-A1 PHARMACEUTICAL COMPOSITION FOR AMELIORATING AUTOIMMUNE-TYPE DISEASES 学校法人近畿大学 2023-12-07 WO disclosed
EP-4253372-A1 PHARMACEUTICAL COMPOSITION FOR AMELIORATING MALIGNANT DISEASES Kinki University (JP) 2023-10-04 EP disclosed
WO-2020162638-A1 COMPOSITION FOR AMELIORATING MALIGNANT TUMOR DISEASES 学校法人近畿大学 2020-08-13 WO disclosed
US-9981963-B2 3-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors JANSSEN PHARMACEUTICA NV (BE) 2018-05-29 US disclosed
EP-3049412-B1 NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-07-12 EP disclosed
US-20160229851-A1 NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS ARGENTA DISCOVERY 2009 LIMITED (GB) 2016-08-11 US disclosed
EP-3049412-A1 NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS Janssen Pharmaceutica, N.V. (BE) 2016-08-03 EP disclosed
CN-105579452-A New 3-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors JANSSEN PHARMACEUTICA NV 2016-05-11 CN disclosed
WO-2015044269-A1 NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260007634-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ALLERGIC DISEASES NFATC1, IL5, TRAF6 DYRK1A 2182/4885NFATC1 1/4885GSK3B 164/4885
US-20160229851-A1 NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS MAP3K14, MAP3K15, MAP3K13 DYRK1A 718/4885NFATC1 177/4885GSK3B 573/4885
US-20240124430-A1 PHARMACEUTICAL COMPOSITION FOR AMELIORATING MALIGNANT DISEASES MINK1, IKBKG, MAP3K20 DYRK1A 2005/4885NFATC1 526/4885GSK3B 724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.